Lineage Cell (Israel) Today
| BTX Stock | ILS 221.60 5.70 2.64% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Lineage Cell is trading at 221.60 as of the 28th of November 2024, a 2.64 percent increase since the beginning of the trading day. The stock's open price was 215.9. Lineage Cell has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Lineage Cell Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. More on Lineage Cell Therapeutics
Moving against Lineage Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Lineage Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Lineage Cell's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Lineage Cell or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Lineage Cell Therapeutics (BTX) is traded on Tel Aviv Stock Exchange in Israel and employs 76 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 512.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lineage Cell's market, we take the total number of its shares issued and multiply it by Lineage Cell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Lineage Cell Therapeutics operates under Healthcare sector and is part of Biotechnology industry.
Lineage Cell Therapeutics has accumulated about 27.1 M in cash with (30.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18.
Check Lineage Cell Probability Of Bankruptcy
Lineage Cell Therapeutics Risk Profiles
Although Lineage Cell's alpha and beta are two of the key measurements used to evaluate Lineage Cell's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.58 | |||
| Standard Deviation | 5.28 | |||
| Variance | 27.89 | |||
| Risk Adjusted Performance | (0.08) |
Lineage Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Lineage Cell without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.